Is it time for a European formulary of paediatric medicines?

The insufficient data leads to inevitable off-label or unlicensed drug use, which may entail a certain degree of risk for patients. 3 This unsatisfactory standing of children with regard to optimal drug therapy is well recognised, especially in the USA and Europe, but the situation in the latter has...

Full description

Saved in:
Bibliographic Details
Published inArchives of disease in childhood Vol. 89; no. 9; pp. 890 - 891
Main Authors Bonati, M, Pandolfini, C
Format Journal Article
LanguageEnglish
Published England BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health 01.09.2004
BMJ Publishing Group LTD
Subjects
Child
Child Health
Childhood Needs
Collaboration
drug labelling
Drug therapy
Drug Use
Europe
European Union
Evidence
formularies
Formularies as Topic
Health Personnel
Humans
Lay People
Letter
Medical personnel
Narcotics
Pediatrics
Pharmaceutical industry
Pharmacists
United Kingdom > UK
Europe
Online AccessGet full text

Cover

More Information
Summary:The insufficient data leads to inevitable off-label or unlicensed drug use, which may entail a certain degree of risk for patients. 3 This unsatisfactory standing of children with regard to optimal drug therapy is well recognised, especially in the USA and Europe, but the situation in the latter has been better defined through numerous studies. 4 Off-label/unlicensed prescription rates are in the range 23-62% in European paediatric hospital wards, 55-80% in neonatal intensive care units, and 11-49% in the community setting. 4 Wide differences in therapeutic approaches were found between and within settings and countries, suggesting the need for "harmonisation" in clinical practice.
Bibliography:ark:/67375/NVC-RM4C861V-G
local:0890890a
PMID:15321879
href:archdischild-89-890-2.pdf
istex:E2766DE8E5284FECA8A39DE35FD9936064E7311B
SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
ISSN:0003-9888
1468-2044
DOI:10.1136/adc.2003.048025